Primary results from a phase 2a study of zanidatamab (zani) plus palbociclib (palbo) plus fulvestrant (fulv) in HER2+/HR+ metastatic breast cancer (mBC)

被引：1
|
作者：
Escriva-de-Romani, Santiago
Cejalvo, Juan Miguel
Alba, Emilio
Friedmann, Jennifer
Lescure, Alvaro Rodriguez
Savard, Marie-France
Pezo, Rossanna C.
Gion, Maria
-Borrego, Manuel Ruiz
Hamilton, Erika
Pluard, Timothy
Webster, Marc
Beeram, Muralidhar
Linden, Hannah
Saura, Cristina
Shpektor, Diana
Salim, Bob
Harvey, Phoebe
Hurvitz, Sara
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-LBO1-04
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBO1-04
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Abemaciclib plus fulvestrant in East Asian women with HR+, HER2-advanced breast cancer: Overall survival from MONARCH 2
    Toi, Masakazu
    Huang, Chiun-Sheng
    Im, Young-Hyuck
    Sohn, Joohyuk
    Zhang, Wei
    Sakaguchi, Sachi
    Haddad, Nadine
    van Hal, Gertjan
    Sledge Jr, George W.
    CANCER SCIENCE, 2023, 114 (01) : 221 - 226
  • [42] A phase I/IIb study of palbociclib (PALBO) plus everolimus (EVE) and exemestane (EXE) in hormone-receptor positive (HR+)/HER2-metastatic breast cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i): Results of the phase II study
    Barroso-Sousa, Romualdo
    Li, Tianyu
    Trippa, Lorenzo
    Rees, Rebecca
    Andrews, Chelsea
    Ferreira, Arlindo R.
    Helvie, Karla
    Partridge, Ann H.
    Overmoyer, Beth
    Winer, Eric P.
    Wagle, Nikhil
    Tolaney, Sara M.
    CANCER RESEARCH, 2020, 80 (04)
  • [43] Results from CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel (T) plus a reduced dose of capecitabine (C) in patients (pts) with hormone receptor plus (HR+), HER2-metastatic breast cancer (MBC) not previously treated with a taxane.
    Schwartzberg, Lee S.
    Bondarenko, Igor
    Tolaney, Sara M.
    Seidman, Andrew David
    O'Shaughnessy, Joyce
    Shparyk, Yaroslav V.
    Chung, Chi-Feng
    Lu, Yen-Shen
    Chic, Nuria
    Panasci, Lawrence C.
    Chae, Yee Soo
    Recalde, Sabela
    Hotko, Yevhen
    Gomez, Patricia
    Shaw Wright, Gail Lynn
    Anthony Dacosta, Noshir
    Vatandoust, Sina
    O'Connell, Joseph P.
    Wei, Thomas
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [44] NETWORK META-ANALYSIS COMPARING PALBOCICLIB PLUS FULVESTRANT WITH EVEROLIMUS PLUS EXEMESTANE FOR HR+/HER2-ADVANCED BREAST CANCER THAT HAS BECOME RESISTANT TO PREVIOUS ENDOCRINE THERAPY
    LeReun, C.
    Gentilini, A.
    Large, S.
    Chowdhury, M.
    Smith, A.
    Rinciog, C.
    VALUE IN HEALTH, 2019, 22 : S446 - S446
  • [45] Early Application of Palbociclib Plus Endocrine Therapy in HR+/HER2-Metastatic Breast Cancer: A Better Choice Based on Data From the Chinese Population
    Zhang, Yusi
    Chen, Wenlin
    Chen, Shuanglong
    Yang, Qingmo
    Ouyang, Zhong
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2022, 21
  • [46] LEONARDA-2: Lerociclib plus letrozole versus placebo plus letrozole in HR+/HER2-advanced or metastatic breast cancer
    Hu, Xichun
    Wang, Biyun
    Wang, Shusen
    Tong, Zhongsheng
    Sun, Tao
    Li, Wei
    Song, Lihua
    Yan, Xi
    Cheng, Ying
    Qiu, Fuming
    Wang, Xinshuai
    Xie, Weimin
    Zhao, Bing
    Liu, Xinlan
    Hu, Changlu
    Lai, Guie
    Pang, Jinke
    Li, Tong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [47] Overall Survival and Exploratory Biomarker Analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus Chemotherapy in HR+, HER2+Metastatic Breast Cancer Patients
    Tolaney, Sara M.
    Goel, Shom
    Nadal, Jorge
    Denys, Hannelore
    Borrego, Manuel R.
    Litchfield, Lacey M.
    Liu, Jiangang
    Appiah, Adams K.
    Chen, Yanyun
    Andre, Fabrice
    CLINICAL CANCER RESEARCH, 2024, 30 (01) : 39 - 49
  • [48] Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer
    Tolaney, Sara M.
    Im, Young-Hyuck
    Calvo, Emiliano
    Lu, Yen-Shen
    Hamilton, Erika
    Forero-Torres, Andres
    Bachelot, Thomas
    Maur, Michela
    Fasolo, Angelica
    Tiedt, Ralph
    Nardi, Lisa
    Stammberger, Uz
    Abdelhady, Ahmed M.
    Ruan, Shiling
    Lee, Soo Chin
    CLINICAL CANCER RESEARCH, 2021, 27 (02) : 418 - 428
  • [49] CAPItello-292: A phase 1b/3 study of capivasertib, palbociclib and fulvestrant versus placebo, palbociclib and fulvestrant in HR+/HER2L advanced breast cancer
    Hamilton, E.
    Schiavon, G.
    Grinsted, L. M.
    De Bruin, E. C.
    Catanese, M. T.
    Rugo, H. S.
    ANNALS OF ONCOLOGY, 2021, 32 : S514 - S514
  • [50] Monarcher: A Randomized Phase 2 Study of Abemaciclib Plus Trastuzumab with or without Fulvestrant Versus Trastuzumab Plus Standard-of-Care Chemotherapy in Women with HR+, HER2+Advanced Breast Cancer
    Ettl, Johannes
    Tolaney, Sara
    Wardley, Andrew
    Zambelli, Stefania
    Hilton, John F.
    Ricci, Francesco
    Im, Seock-Ah
    Kim, Sung-Bae
    Johnston, Stephen
    Chan, Arlene
    Goel, Shom
    Catron, Kristen
    Yang, Zhengyu
    Gainford, Corona
    Andre, Fabrice
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 16 - 16
12345